Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis

Journal of Neuroimmunology

Volumn 244, Issue 1-2, 2012, Pages 1-7

  Mori, Shuuichi ^a   Yamada, Shigeru ^a   Kubo, Sachiho ^a   Chen, Jie ^b   Matsuda, Seiji ^b   Shudou, Masachika ^b   Maruyama, Naoki ^a   Shigemoto, Kazuhiro ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibodies; Dok 7; MuSK; Myasthenia gravis

Indexed keywords

AGRIN; AUTOANTIBODY; BINDING PROTEIN; CHOLINERGIC RECEPTOR; MUSCLE SPECIFIC KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MYASTHENIA GRAVIS; MYOTUBE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PARESIS; PATHOGENESIS; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RABBIT;

AGRIN; ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RABBITS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 84857914720     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.12.005     Document Type: Article

References (26)

1. Akaaboune M., Grady R.M., Turney S., Sanes J.R., Lichtman J.W. Neurotransmitter receptor dynamics studied in vivo by reversible photo-unbinding of fluorescent ligands. Neuron 2002, 34:865-876.
2. Anderson J.A., Ng J.J., Bowe C., McDonald C., Richman D.P., Wollmann R.L., Maselli R.A. Variable phenotypes associated with mutations in DOK7. Muscle Nerve 2008, 37:448-456.
3. Beeson D., Higuchi O., Palace J., Cossins J., Spearman H., Maxwell S., Newsom-Davis J., Burke G., Fawcett P., Motomura M., Muller J.S., Lochmuller H., Slater C., Vincent A., Yamanashi Y. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006, 313:1975-1978.
4. Benveniste O., Jacobson L., Farrugia M.E., Clover L., Vincent A. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J. Neuroimmunol. 2005, 170:41-48.
5. Chevessier F., Faraut B., Ravel-Chapuis A., Richard P., Gaudon K., Bauche S., Prioleau C., Herbst R., Goillot E., Ioos C., Azulay J.P., Attarian S., Leroy J.P., Fournier E., Legay C., Schaeffer L., Koenig J., Fardeau M., Eymard B., Pouget J., Hantai D. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum. Mol. Genet. 2004, 13:3229-3240.
6. Chevessier F., Girard E., Molgo J., Bartling S., Koenig J., Hantai D., Witzemann V. A mouse model for congenital myasthenic syndrome due to MuSK mutations reveals defects in structure and function of neuromuscular junctions. Hum. Mol. Genet. 2008, 17:3577-3595.
7. Cole R.N., Reddel S.W., Gervasio O.L., Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 2008, 63:782-789.
8. Cole R.N., Ghazanfari N., Ngo S.T., Gervasio O.L., Reddel S.W., Phillips W.D. Patient autoantibodies deplete postsynaptic Muscle Specific Kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J. Physiol. 2010, 588:3217-3229.
9. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 2006, 116:2843-2854.
10. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., Kinetz E., Compton D.L., Rojas E., Park J.S., Smith C., DiStefano P.S., Glass D.J., Burden S.J., Yancopoulos G.D. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996, 85:501-512.
11. Engel A.G., Tsujihata M., Lambert E.H., Lindstrom J.M., Lennon V.A. Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J. Neuropathol. Exp. Neurol. 1976, 35:569-587.
12. Hopf C., Hoch W. Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes. J. Biol. Chem. 1998, 273:6467-6473.
13. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., Beeson D., Willcox N., Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
14. Lu Z., Je H.S., Young P., Gross J., Lu B., Feng G. Regulation of synaptic growth and maturation by a synapse-associated E3 ubiquitin ligase at neuromuscular junction. J. Cell Biol. 2007, 177:1077-1089.
15. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 2004, 55:580-584.
16. Mori, S., Kubo, S., Akiyoshi, T., Yamada, S., Miyazaki, T., Hotta, H., Dezaki, J., Kishi, M., Konishi, T., Nishino, Y., Miyazawa, A., Maruyama, N., Shigemoto, K., in press. Antibodies against Muscle-Specific Kinase Impair Both Presynaptic and Postsynaptic Functions in a Murine Model of Myasthenia Gravis. Am. J. Pathol. doi:10.1016/j.ajpath.2011.10.031.
17. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol 2007, 26:5-10.
18. Oh S.J. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J. Clin. Neurol. 2009, 5:53-64.
19. Ohta K., Shigemoto K., Fujinami A., Maruyama N., Konishi T., Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur. J. Neurol. 2007, 14:1029-1034.
20. Okada K., Inoue A., Okada M., Murata Y., Kakuta S., Jigami T., Kubo S., Shiraishi H., Eguchi K., Motomura M., Akiyama T., Iwakura Y., Higuchi O., Yamanashi Y. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006, 312:1802-1805.
21. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., Kobayashi N., Mominoki K., Abe Y., Ueda N., Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 2006, 116:1016-1024.
22. Shigemoto K., Kubo S., Jie C., Hato N., Abe Y., Ueda N., Kobayashi N., Kameda K., Mominoki K., Miyazawa A., Ishigami A., Matsuda S., Maruyama N. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann. N. Y. Acad. Sci. 2008, 1132:93-98.
23. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 2005, 57:289-293.
24. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
25. Vincent A., Lang B., Kleopa K.A. Autoimmune channelopathies and related neurological disorders. Neuron 2006, 52:123-138.
26. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., Benveniste O., Morgan B.P., Hilton-Jones D., Newsom-Davis J., Beeson D., Willcox N. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann. N. Y. Acad. Sci. 2008, 1132:84-92.